

## PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma

Wanglong Qiu,<sup>1</sup> Frank Schönleben,<sup>1</sup> Xiaojun Li,<sup>1</sup> Daniel J. Ho,<sup>1</sup> Lanny G. Close,<sup>1</sup> Spiros Manolidis,<sup>1</sup> Boyce P. Bennett,<sup>2</sup> and Gloria H. Su<sup>1,2</sup>

**Abstract Purpose:** Recent studies have reported high frequencies of somatic mutations in the phosphoinositide-3-kinase catalytic  $\alpha$  (*PIK3CA*) gene in several human solid tumors. Although gene amplifications of *PIK3CA* have been reported in head and neck squamous cell carcinoma (HNSCC), small mutation of the gene has not been evaluated in HNSCC previously. In this study, we examined the mutation frequency of *PIK3CA* in HNSCC.

**Experimental Design:** More than 75% of the somatic mutations of *PIK3CA* are clustered in the helical (exon 9) and kinase domains (exon 20). To investigate the possible role of *PIK3CA* in HNSCC tumorigenesis, exons 1, 4, 5, 6, 7, 9, and 20 of the gene were analyzed by direct genomic DNA sequencing in 38 HNSCC specimens.

**Results:** We identified four missense mutations in the seven exons of *PIK3CA* from 38 HNSCC specimens (11%). Three of the four mutations (i.e., H1047R, E542K, and E545K) have been previously reported as hotspot mutations. The remaining novel mutation, Y343C, is identified at exon 4 nucleotide 1028 A  $\rightarrow$  G. Three of the four mutations were shown to be somatic, whereas the fourth mutation (H1047R) was identified in a cell line. Interestingly, three of the four mutations identified were in pharyngeal cancer samples.

**Conclusions:** These data provide evidence that oncogenic properties of *PIK3CA* contribute to the carcinogenesis of human head and neck cancers, especially in pharyngeal cancer. A specific kinase inhibitor to *PIK3CA* may potentially be an effective therapeutic reagent against HNSCC or pharyngeal cancer in particular.

The phosphatidylinositol 3-kinase (PI3K) signaling pathway regulates many normal cellular processes, such as cell proliferation, survival, and apoptosis (1–3). Dysregulation or genetic aberration of components of this pathway, including *AKT*, *PTEN*, and *PIK3CA*, has been associated with cancer development (4–12).

*PIK3CA* is located on chromosome 3q26.32 and encodes for the catalytic subunit p110 $\alpha$  of class IA PI3K. It has been implicated to function as an oncogene in human cancer because of its elevated kinase activity and genomic amplification in tumor samples (7–12). Recently, high frequencies of somatic mutations in the *PIK3CA* gene have been reported in several human cancer types, including colon, brain, stomach, breast, and ovary (13–18). More than 75% of these mutations are clustered in the helical (exon 9) and kinase domains (exon 20) of the gene (13). The three most frequently reported

mutation hotspots in *PIK3CA* (i.e., E542K, E545K, and H1047R) have been shown to elevate its lipid kinase activity and lead to the activation of the downstream Akt signaling pathway (13, 19). Interestingly, *PIK3CA* mutations and *PTEN* loss are nearly mutually exclusive, suggesting that the homeostasis of phosphatidylinositol-3,4,5-triphosphate regulated by both *PIK3CA* and *PTEN* is critical to carcinogenesis (20). This further evinced the importance of the *PI3K* pathway in the tumorigenesis of many cancer types.

Although the *PIK3/AKT/PTEN* pathway has been implicated in head and neck squamous cell carcinoma (HNSCC; refs. 12, 21–23), no genetic mutation of *PIK3CA* has been described to date. To investigate whether *PIK3CA*-activating mutation is a common mechanism involved in the tumorigenesis of HNSCC, we analyzed for genetic alterations of the *PIK3CA* gene in 38 HNSCC specimens, including eight cell lines, by direct genomic DNA sequencing. Only exons 1, 4, 5, 6, 7, 9, and 20 of the gene were sequenced in these specimens because they covered the most common *PIK3CA* mutations previously observed in human cancer (13–17, 24–26).

### Materials and Methods

**Tissue samples and cell lines.** Eight HNSCC cell lines (RPMI 2650, A-253, SW579, Detroit 562, FADU, CAL 27, SCC-15, and SCC-25) were purchased from the American Type Culture Collection (Rockville, MD). The cell lines were maintained as recommended by the American Type Culture Collection.

Thirty frozen primary tumor samples and their corresponding match normal muscle specimens were obtained from the Tumor Bank facility of the Herbert Irving Comprehensive Cancer Center and Department of

**Authors' Affiliations:** Departments of <sup>1</sup>Otolaryngology/Head and Neck Surgery and <sup>2</sup>Pathology, Columbia University College of Physicians and Surgeons, New York, New York

Received 10/4/05; revised 11/10/05; accepted 12/15/05.

**Grant support:** National Cancer Institute Temin Award grant CA95434 and National Cancer Institute grant R01 CA109525.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

**Requests for reprints:** Gloria H. Su, Department of Otolaryngology/Head and Neck Surgery, Columbia University College of Physicians and Surgeons, 1130 St. Nicholas Avenue, ICRC 10-04, New York, NY 10032. Phone: 212-851-4624; E-mail: gs2157@columbia.edu.

© 2006 American Association for Cancer Research.

doi:10.1158/1078-0432.CCR-05-2173

Otolaryngology/Head and Neck Surgery of the Columbia University Medical Center. Acquisition of the tissue specimens was approved by the Institutional Review Board of Columbia University Medical Center and done in accordance with Health Insurance Portability and Accountability Act regulations. Fresh-frozen tumor samples were dissected to ensure that the specimen contained at least 75% cancer cells. The cancer sites were nasal cavity (2), pharynx (6), larynx (10), oral cavity (8), and other sites (4). The patients' ages ranged from 40 to 85 years (average,  $64.0 \pm 14.5$  years). The grades of the tumors were moderately to poorly differentiated.

**PCR amplification and PCR product direct sequencing.** Genomic DNAs were extracted from the cell lines and the frozen tissue samples using DNeasy tissue kit (Qiagen, Valencia, CA). The procedures were done according to the manufacturer's instructions.

Exons 1, 4, 5, 6, 7, 9, and 20 of the *PIK3CA* gene were analyzed by PCR amplification of genomic DNA and PCR product direct sequencing. Genomic DNAs (40 ng per sample) were amplified with primers covering the entire coding region and the exon/intron boundaries of the desired exons (*PIK3CA*-E9F, 5'-CTGTGAATCCAGAGGGGAAA-3'; *PIK3CA*-E9R, 5'-GCATTTAATGTGCCAACTACCA-3'; *PIK3CA*-E9FS, 5'-TCCAGAGGGGAAAATATGACA-3'; ref. 13). All gene sequencings were done with ABI's 3100 capillary automated sequencers at the DNA facility of Columbia University Medical Center using previously published sequencing primers (13). All samples found to have a genetic alteration in the target were subsequently sequenced in the reverse direction to confirm the mutation using the reverse PCR primers (13). The mutation was then further verified by sequencing of a second PCR product derived independently from the original template.


## Results

**A novel sequence identified similar to *PIK3CA*.** Although sequencing for mutations using primers we had designed for exon 9, we were surprised to find an alteration at nucleotide 1634 A → C (E545A) in all the cases (Figs. 1 and 2). However, this nucleotide change of *PIK3CA* A1634C (E545A) always coexisted with another alteration of G → C at nucleotide 1658 and a base deletion at nucleotide 1659 (Fig. 1). Subsequent sequencing analyses of the matching normal tissue specimens revealed that the same nucleotide changes occurred in both tumor and normal tissues (data not shown). This unusual result led us to blast search this PCR fragment (410-bp long) in the Genbank. We found two genomic DNA clones that contain

fragments that are 97% (401 of 410) homologous to the exon 9 and its flanking intronic sequences. These two clones are located at chromosome 22q11.2 cat eye syndrome region (gi 5931525) and at chromosome 16 (gi 28913054; Fig. 2; data not shown). Further comparisons of the sequences using the BLAST search revealed that both genomic clones on chromosomes 22 and 16 contain sequences highly homologous to the exons 9, 11 to 13, and partial exon 10 of the *PIK3CA* gene (data not shown). An automatic computational analysis using the GNOMON gene prediction method predicted a protein that can be transcribed and translated from the chromosome 22 clone. The predicted protein (gi 51475436) is similar to the helical domain of the *PIK3CA* protein. However, this sequence homologue is likely to be a pseudogene because no RNA transcripts of the predicted protein can be detected by reverse transcription-PCR (data not shown).


This sequence homologue was probably not reported by previous publications because its detectability depends highly on primer designs. When we moved the PCR primer sites, used the primers published in the study by Samuels et al. (13), or increased the stringency of our PCR condition, all the nucleotide alterations, including the so-called *PIK3CA* A1634C (E545A) "mutation" disappeared. We concluded that the A1634C (E545A) "mutation" observed in our hands was an artifact created by interferences from the sequence homologue.

***PIK3CA* is activated by small mutation in HNSCC.** Four missense mutations of the *PIK3CA* gene were identified in the 38 HNSCC specimens (Fig. 3; Table 1): two of the mutations were in the exon 9 (E545K and E542K), one was in the exon 20 (H1047Y), and one was in the exon 4 (Y343C). None of these mutations was detected in the corresponding normal tissues except for the H1047Y mutation, which was identified in HNSCC cell line Detroit 562. Three of the four *PIK3CA* missense mutations (E545K, E542K, and H1047R) are previously described hotspot mutations (13). Functional studies showed that PI3K carrying any one of the three hotspot mutations is able to induce transformation in cultures of chicken embryo fibroblasts, and that the transforming activity of the mutant is correlated with increased lipid kinase activity and activation of the Akt signaling pathway (13, 19). The mutation in the exon 4 nucleotide 1028 A → G, which leads to



**Fig. 1.** Identification of a sequence similar to *PIK3CA* on chromosomes 22 and 16. *A* and *B*, so-called A1634C (E545A) "mutation" of the *PIK3CA* gene detected in all of our tumor samples. In our study, this "mutation" (black arrow) always coexisted with G1658C (red arrow) and a deletion of nucleotide 1659T. This sequencing profile was also detected in the matching normal specimens. We subsequently concluded that this abnormal profile is caused by the interference of a DNA sequence that is located at chromosome 22q11.2 cat eye syndrome region and chromosome 16 that are 97% homologous to the exon 9 of the *PIK3CA* gene.

**Fig. 2.** Alignment of a PCR fragment of the *PIK3CA* gene containing exon 9 and its flanking intronic sequences with a human genomic DNA clone located at chromosome 22q11.2 cat eye syndrome region (gi 5931525). The alignment shows that the homology between the two pieces of nucleotide sequences is 97% (401 of 410). Arrows mark the three nucleotide differences located inside the exon 9 coding region (in top cases). The PCR primers designed by us (*PIK3CA-E9F* and *PIK3CA-E9R*) and Samuel et al. (hCT1640694-Ex9F and hCT1640694-Ex9R) are underlined.




alteration at codon 343 TAC (Y) → TGC(C), has not been described before (Fig. 3).

Two other nucleotide alterations were also detected in the exonic regions of the *PIK3CA* gene (Table 1). One alteration, located at the exon 6 nucleotide 1173 A → G [codon 391 ATA (Ile) → ATG (Met)] was found in six HNSCC tumor specimens.

This nucleotide alteration was also detected in the six matching normal tissues. A search of the SNP database revealed that A1173G is a known SNP (rs2230461) that has been validated by multiple PCR reactions and genotype data. Thus, we conclude that this germ line alteration represents a non-disease-causing polymorphism of *PIK3CA*. Another exonic

**Fig. 3.** *PIK3CA* mutations found in HNSCC. Three of the four mutations (E545K, E542K, and Y343C) were confirmed to be somatic in sporadic HNSCC. The H1047R mutation was found in a HNSCC cell line.



**Table 1.** Nucleotide alterations within the coding exons of *PIK3CA* identified in 38 HNSCC specimens

Cases	Exon	Nucleotide	Amino acid	Present in normal tissue	Tumor site (n)
Detroit 562	20	A3140G	H1047R	NA	Pharynx (1)
102T	9	G1624A	E542K	No	Oropharynx (1)
109T	9	G1633A	E545K	No	Hypopharynx (1)
182T	4	A1028G	Y343C	No	Tongue (1)
80T	5	C1143G	P381P	Yes	Tongue (1)
6 cases	6	A1173G	I391M	Yes	Pharynx (2) oral (2) Larynx(1) neck (1)

NOTE: The nucleotide alterations are described according to the cDNA sequence with Genbank accession no. NM\_006218.  
Abbreviation: NA, not available.

alteration was also deemed a polymorphism because it occurred at exon 5 C1143G (P381P) without resulting in an amino acid change and was observed in both the tumor and normal samples of one tongue cancer patient. All of the polymorphisms observed in the intronic regions flanking the seven exons of *PIK3CA* examined in this study are listed in Table 2. These polymorphisms are unlikely to cause significant changes in the function of *PIK3CA*.

## Discussion

The mutation frequency of *PIK3CA* has been reported at 32% in colon cancer, ~4% to 25% in gastric cancer, 8% to 40% in breast cancer, 5% to 27% in brain cancer, 4% in lung cancer, and 4% to 7% in ovarian cancer (13, 16–18, 25). In the present study, we report 11% (4 of 38) of *PIK3CA* mutations in sporadic HNSCC. Interestingly, three of the four cases with mutations are from the same organ site, pharynx (Table 1). Cancer of the pharynx is the ninth most common cancer worldwide (27). It is characterized as the following subsites: posterior pharynx, hypopharynx, and lateral pharyngeal walls. A total of six pharyngeal squamous cell carcinoma cases were examined in this study, suggesting that as high as 50% (3 of 6) of pharyngeal tumor samples may harbor *PIK3CA* mutations. These data are

supported by a previous report that showed chromosome 3q26 is amplified in 100% of nasopharyngeal carcinoma (22). However, from the present study, we are unable to conclude the exact mutational frequency of *PIK3CA* in pharyngeal carcinomas and comment on which subtype of pharyngeal carcinomas (nasopharynx, oropharynx, and hypopharynx) is targeted for *PIK3CA* mutation. Among our six pharyngeal samples, there was one oropharyngeal cancer sample, one hypopharyngeal cancer, and four that were not subtyped. More studies with larger sample sizes and various pharyngeal subtypes are necessary to further investigate these potentials.

Gene amplification is a more commonly observed mechanism of oncogene activation in HNSCC than small genetic mutation. *Cyclin D1* gene amplification has been observed in ~34% to 37% of HNSCC (28, 29). *EGF* receptor gene amplification has been reported in 7% to 19% of HNSCC (30–32). In contrast, *RAS* mutation is relatively rare in HNSCC compared with other solid cancers: <6% in HNSCC versus 99% in pancreatic cancer and 37% to 47% in colorectal cancer (33–39). Amplification of chromosome 3q26 is frequently observed in HNSCC and is linked to tumor progression and negatively correlated with clinical outcome (40–42). Gene amplification and overexpression of *PIK3CA* are observed in low to moderate dysplastic cases, but their increased frequencies are associated with transition to invasive cancer (21, 23). Here, we showed that gene amplification is not the only mechanism to activate *PIK3CA* in HNSCC. Small mutation and gene amplification both contribute to the activation of *PIK3CA* in HNSCC.

In summary, we report missense mutations of the *PIK3CA* gene in HNSCC (4 of 38, 11%). Among the four cases identified here, the Y343C mutation, which is located at *PIK3CA* exon 4 nucleotide 1028 A → G, is novel and has not been described in previous studies. Although the physiologic significance of the novel mutation Y343C, which is located within the *PIK3CA* C2 domain, is not known, it has been shown that the C2 domain in the class IB PI3K interacts primarily with the helical domain and also interacts with the linker segment before the Ras-binding domain and with the COOH-terminal lobe of the catalytic domain (43). The C2 domain is often involved in Ca<sup>2+</sup>-dependent or Ca<sup>2+</sup>-independent phospholipids membrane binding. By analogy, with enzymes like protein kinase C and cytosolic phospholipase A2, the C2 domain of class IB PI3K might participate in Ca<sup>2+</sup>-independent phospholipids membrane binding (43). Because mutations found in the C2 domain account for 7% of total

**Table 2.** Polymorphisms of *PIK3CA* found in 38 HNSCC specimens

Nucleotide position	Allele/allele frequency (n)
IVS 1 +43 A > G	A/G (13) A/A (14) G/G (1)
+130 insert TAT	Hetero (13) Homo (1)
IVS 4 -69 G > T	G/T (15) G/G (23) T/T (0)
-17 A > T	A/T (15) A/A (16) C/C (7)
+62 C > A	C/A (13) C/C (13) A/A (12)
IVS 5 -38 T > C	T/C (4) T/T (34) C/C (0)
+54 G > A	G/A (15) G/G (14) A/A (9)
+307G > A	G/A (15) G/G (14) A/A (9)
IVS 7 +42 del TC	Hetero (1)
IVS 9 +105 T > G	T/G (4) T/T (34) G/G (0)

NOTE: The nucleotide alterations are described according to the genomic DNA sequences of *PIK3CA* (gi 8705172).  
Abbreviations: Hetero, heterozygosity; Homo, homozygosity.

*PIK3CA* mutations found in a study of 396 cancer samples (13), it will be worthwhile to determine the exact function of the C2 domain of class 1A PI3K in future studies. The other three are hotspot mutations (E545K, E542K, and H1047R), and all were found in pharyngeal cancer patients. The smoking histories of the mutated patients are unknown. We did not find any significant correlation of the *PIK3CA* gene mutation to the gender or age of the patients.

Here, we also report the discovery of a *PIK3CA* homologue. This homologue is almost identical to the exons 9, 11 to 13, and partial exon 10 of the *PIK3CA* gene and can be found on both chromosomes 16 and 22. However, we think that this sequence homolog is likely to be a pseudogene because no RNA transcripts of the predicted protein can be detected by reverse transcription-PCR. In our study, interferences from this sequence homologue had caused confusions by creating nucleotide alterations, including the so-called *PIK3CA* A1634C (E545A) "mutation" (Figs. 1 and 2), which subsequently vanished with better primer designs and more stringent PCR conditions. Intriguingly, this A1634C (E545A) mutation has been previously reported in human cancers by two publications. One study described 11 cases with the A1634C (E545A) mutation out of 73 hepatocellular carcinomas (15). More recently, this exact mutation was reported to contribute up to 88% (21 of 24) of the total *PIK3CA* mutations identified in ovarian cancer (24). This mutation was not described in other reports on *PIK3CA* mutation (13, 14, 16–18, 25, 26). In light of our discovery, it is important for future studies to be aware of the possible interference from the homologous

sequences on chromosomes 22 and 16. Although we did not study exons 10 to 13 in our current study, potential artifacts there are also probable.

Our data confirm that *PIK3CA* is important to HNSCC tumorigenesis and provide evidence that small mutation can also contribute to oncogene activation of *PIK3CA* in HNSCC. Furthermore, our data suggest that *PIK3CA* gene mutations may be more involved in the carcinogenesis of a particular subset of human head and neck cancers (pharyngeal cancers) than others. The knowledge of the *PIK3CA*'s involvement in HNSCC is important because a specific kinase inhibitor could be considered as a future therapeutic option for HNSCC patients with *PIK3CA* mutations. Most HNSCC are diagnosed at advanced stage and are usually unresectable despite significant surgical advances. Improvements in chemotherapy and radiotherapy in recent decades have not been translated into better prognosis of HNSCC patients (44). Recently kinase inhibitors such as Gleevec (Imatinib), Herceptin (Trastuzumab), and Iressa (Gefitinib) have been successfully developed for therapies in some cancer types (45). Because amplification and overexpression of the *PIK3CA* gene locus is an early oncogenic event of HNSCC tumorigenesis and is also correlated to invasion (21, 23), abrogation of its oncogenic activities may conceivably slow or stop tumor progression. It is believed that such a selective small-molecule inhibitor against *PIK3CA* would have tremendous potential as a novel cancer chemotherapeutic for HNSCC (46). Our findings further supports *PIK3CA* as an important potential target in head and neck cancer for pathway-specific, kinase inhibitor-based therapies.

## References

- Klippel A, Escobedo MA, Wachowicz MS, et al. Activation of phosphatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation. *Mol Cell Biol* 1998;18:5699–711.
- Chang HW, Aoki M, Fruman D, et al. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. *Science* 1997;276:1848–50.
- Kennedy SG, Wagner AJ, Conzen SD, et al. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. *Genes Dev* 1997;11:701–13.
- Yuan ZQ, Sun M, Feldman RI, et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. *Oncogene* 2000;19:2324–30.
- Bellacosa A, de Feo D, Godwin AK, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. *Int J Cancer* 1995;64:280–5.
- Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. *Proc Natl Acad Sci U S A* 1999;96:4240–5.
- Phillips WA, St Clair F, Munday AD, Thomas RJ, Mitchell CA. Increased levels of phosphatidylinositol 3-kinase activity in colorectal tumors. *Cancer* 1998;83:41–7.
- Benistant C, Chapuis H, Roche S. A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in *de novo* DNA synthesis of human colon carcinoma cells. *Oncogene* 2000;19:5083–90.
- Andrew S. *PIK3CA*: determining its role in cellular proliferation and ovarian cancer. *Clin Genet* 1999;56:190–1.
- MaYY, Wei SJ, LinYC, et al. *PIK3CA* as an oncogene in cervical cancer. *Oncogene* 2000;19:2739–44.
- Shayesteh L, Lu Y, Kuo WL, et al. *PIK3CA* is implicated as an oncogene in ovarian cancer. *Nat Genet* 1999;21:99–102.
- Pedrero JM, Carracedo DG, Pinto CM, et al. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. *Int J Cancer* 2005;114:242–8.
- Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the *PIK3CA* gene in human cancers. *Science* 2004;304:554.
- Bachman KE, Argani P, Samuels Y, et al. The *PIK3CA* gene is mutated with high frequency in human breast cancers. *Cancer Biol Ther* 2004;3:772–5.
- Lee JW, Soung YH, Kim SY, et al. *PIK3CA* gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. *Oncogene* 2004;24:1477–80.
- Campbell IG, Russell SE, Choong DY, et al. Mutation of the *PIK3CA* gene in ovarian and breast cancer. *Cancer Res* 2004;64:7678–81.
- Broderick DK, Di C, Parrett TJ, et al. Mutations of *PIK3CA* in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. *Cancer Res* 2004;64:5048–50.
- Wang Y, Helland A, Holm R, Kristensen GB, Borresen-Dale AL. *PIK3CA* mutations in advanced ovarian carcinomas. *Hum Mutat* 2005;25:322.
- Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. *Proc Natl Acad Sci U S A* 2005;102:802–7.
- Saal LH, Holm K, Maurer M, et al. *PIK3CA* mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. *Cancer Res* 2005;65:2554–9.
- Estilo CL, O-Charenrat P, Ngai I, et al. The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue. *Clin Cancer Res* 2003;9:2300–6.
- OrYY, Hui AB, Tam KY, Huang DP, Lo KW. Characterization of chromosome 3q and 12q amplicons in nasopharyngeal carcinoma cell lines. *Int J Oncol* 2005;26:49–56.
- Woenckhaus J, Steger K, Werner E, et al. Genomic gain of *PIK3CA* and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma. *J Pathol* 2002;198:335–42.
- Levine DA, Bogomolny F, Yee CJ, et al. Frequent mutation of the *PIK3CA* gene in ovarian and breast cancers. *Clin Cancer Res* 2005;11:2875–8.
- Li VS, Wong CW, Chan TL, et al. Mutations of *PIK3CA* in gastric adenocarcinoma. *BMC Cancer* 2005;5:29.
- Samuels Y, Velculescu VE. Oncogenic mutations of *PIK3CA* in human cancers. *Cell Cycle* 2004;3:1221–4.
- Blanchaert RH, Jr. Oral and oral pharyngeal cancer: an update on incidence and epidemiology, identification, advances in treatment, and outcomes. *Compend Contin Educ Dent* 2002;23:25–9.
- Callender T, el-Naggar AK, Lee MS, Frankenthaler R, Luna MA, Batsakis JG. PRAD-1 (CCND1)/cyclin D1 oncogene amplification in primary head and neck squamous cell carcinoma. *Cancer* 1994;74:152–8.
- Jares P, Fernandez PL, Campo E, et al. PRAD-1/cyclin D1 gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas. *Cancer Res* 1994;54:4813–7.
- Kearsley JH, Leonard JH, Walsh MD, Wright GR. A comparison of epidermal growth factor receptor (EGFR) and c-erbB-2 oncogene expression in head and neck squamous cell carcinomas. *Pathology* 1991;23:189–94.
- Ishitoya J, Toriyama M, Oguchi N, et al. Gene amplification and overexpression of EGF receptor in

- squamous cell carcinomas of the head and neck. *Br J Cancer* 1989;59:559–62.
32. Leonard JH, Kearsley JH, Chenevix-Trench G, Hayward NK. Analysis of gene amplification in head-and-neck squamous-cell carcinoma. *Int J Cancer* 1991;48:511–5.
33. Anderson JA, Irish JC, Ngan BY. Prevalence of RAS oncogene mutation in head and neck carcinomas. *J Otolaryngol* 1992;21:321–6.
34. Yarbrough WG, Shores C, Witsell DL, Weissler MC, Fidler ME, Gilmer TM. ras mutations and expression in head and neck squamous cell carcinomas. *Laryngoscope* 1994;104:1337–47.
35. Weber A, Langhanki L, Sommerer F, Markwarth A, Wittekind C, Tannapfel A. Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. *Oncogene* 2003;22:4757–9.
36. Almoguerra C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. *Cell* 1988;53:549–54.
37. Rozenblum E, Schutte M, Goggins M, et al. Tumor-suppressive pathways in pancreatic carcinoma. *Cancer Res* 1997;57:1731–4.
38. Bos JL, Fearon ER, Hamilton SR, et al. Prevalence of ras gene mutations in human colorectal cancers. *Nature* 1987;327:293–7.
39. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. *N Engl J Med* 1988;319:525–32.
40. Hashimoto Y, Oga A, Kawauchi S, et al. Amplification of 3q26 approximately qter correlates with tumor progression in head and neck squamous cell carcinomas. *Cancer Genet Cytogenet* 2001;129:52–6.
41. Liehr T, Ries J, Wolff E, et al. Gain of DNA copy number on chromosomes 3q26-qter and 5p14-pter is a frequent finding in head and neck squamous cell carcinomas. *Int J Mol Med* 1998;2:173–9.
42. Singh B, Stoffel A, Gogineni S, et al. Amplification of the 3q26.3 locus is associated with progression to invasive cancer and is a negative prognostic factor in head and neck squamous cell carcinomas. *Am J Pathol* 2002;161:365–71.
43. Walker EH, Perisic O, Ried C, Stephens L, Williams RL. Structural insights into phosphoinositide 3-kinase catalysis and signalling. *Nature* 1999;402:313–20.
44. Seiwert TY, Cohen EE. State-of-the-art management of locally advanced head and neck cancer. *Br J Cancer* 2005;92:1341–8.
45. Couzin J. Cancer drugs. Smart weapons prove tough to design. *Science* 2002;298:522–5.
46. Rogers SJ, Box C, Harrington KJ, Nutting C, Rhys-Evans P, Eccles SA. The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck. *Expert Opin Ther Targets* 2005;9:769–90.

# Clinical Cancer Research

## **PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma**

Wanglong Qiu, Frank Schönleben, Xiaojun Li, et al.

*Clin Cancer Res* 2006;12:1441-1446.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/12/5/1441>

**Cited articles** This article cites 45 articles, 14 of which you can access for free at:  
<http://clincancerres.aacrjournals.org/content/12/5/1441.full.html#ref-list-1>

**Citing articles** This article has been cited by 24 HighWire-hosted articles. Access the articles at:  
</content/12/5/1441.full.html#related-urls>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, contact the AACR Publications Department at [permissions@aacr.org](mailto:permissions@aacr.org).